A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

NCT02135107 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

517

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: Rabeprazole
DRUG: Rabeprazole
DRUG: Rabeprazole
DRUG: Rabeprazole

Sponsor

Eisai Co., Ltd.